Gene therapy with the TRF 1 telomere gene rescues decreased TRF 1 levels with aging and prolongs mouse health span
Open accessThe DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Summary: The shelterin complex protects telomeres by preventing them from being degraded and recognized as double‐strand DNA breaks. TRF 1 is an essential component of shelterin, with important roles in telomere protection and telomere replication. We previously showed that TRF 1 deficiency in the context of different mouse tissues leads to loss of tissue homeostasis owing to impaired stem cell function. Here, we show that TRF 1 levels decrease during organismal aging both in mice and in humans. We further show that increasing TRF 1 expression in both adult (1‐year‐old) and old (2‐year‐old) mice using gene therapy can delay age‐associated pathologies. To this end, we used the nonintegrative adeno‐associated serotype 9 vector (AAV 9), which transduces the majority of mouse tissues allowing for moderate and transient TRF 1 overexpression. AAV 9‐TRF 1 gene therapy significantly prevented age‐related decline in neuromuscular function, glucose tolerance, cognitive function, maintenance of subcutaneous fat, and chronic anemia. Interestingly, although AAV 9‐TRF 1 treatment did not significantly affect median telomere length, we found a lower abundance of short telomeres and of telomere‐associated DNA damage in some tissues. Together, these findings suggest that rescuing naturally decreased TRF 1 levels during mouse aging using AAV 9‐TRF 1 gene therapy results in an improved mouse health span.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
López-Otín, C., Blasco, M. A., Partridge, L., Serrano, M., & Kroemer, G. (2013) · Cell · doi:10.1016/j.cell.2013.05.039 · Cited by 14,982
Self-citationShelterin: the protein complex that shapes and safeguards human telomeres
de Lange, T. (2005) · Genes & Development · doi:10.1101/gad.1346005 · Cited by 3,056 · cited 2×
“…at the end of linear chromosomes that consist of TTAGGG repeats bound by an array of associated proteins known as shelterin, which prevent chromosome ends from being recognized as double-strand DNA breaks and from chromosome end-to-end fusions (reviewed in de Lange, 2005; Blackburn, 2000).”
Telomere Shortening and Tumor Formation by Mouse Cells Lacking Telomerase RNA
Blasco, M. A., Lee, H.-W., Hande, M. P., Samper, E., Lansdorp, P. M., DePinho, R. A., & Greider, C. W. (1997) · Cell · doi:10.1016/s0092-8674(01)80006-4 · Cited by 2,108
Self-citationOlovnikov (1973) · doi:10.1016/0022-5193(73)90198-7 · Cited by 1,847
WATSON, J. D. (1972) · Nature New Biology · doi:10.1038/newbio239197a0 · Cited by 1,632 · cited 1×
“…cells as a solution to the ‘end-replication problem’, which refers to the incomplete DNA replication of the ends of linear chromosomes by the DNA replication machinery (Watson, 1972; Olovnikov, 1973), thus leading to telomere shortening with each round of cell division (Harley et al., 1990).”
BackgroundAnalysis of AAV Serotypes 1–9 Mediated Gene Expression and Tropism in Mice After Systemic Injection
Zincarelli, C., Soltys, S., Rengo, G., & Rabinowitz, J. E. (2008) · Molecular Therapy · doi:10.1038/mt.2008.76 · Cited by 1,490 · cited 1×
“This pattern of overexpression of TRF1 using AAV9 is consistent with previous reports (Zincarelli et al., 2008; Bernardes de Jesus et al., 2012; Schuster et al., 2014).”
ResultInk4a/Arf expression is a biomarker of aging
Krishnamurthy, J., Torrice, C., Ramsey, M. R., Kovalev, G. I., Al-Regaiey, K., Su, L., & Sharpless, N. E. (2004) · Journal of Clinical Investigation · doi:10.1172/jci22475 · Cited by 1,486
Essential role of mouse telomerase in highly proliferative organs
Lee, H.-W., Blasco, M. A., Gottlieb, G. J., Horner, J. W., Greider, C. W., & DePinho, R. A. (1998) · Nature · doi:10.1038/33345 · Cited by 1,270 · cited 1×
“Telomere shortening has been demonstrated to be sufficient to trigger age-related pathologies and shorten lifespan in mice (Blasco et al., 1997; Lee et al., 1998; Blasco, 2005).”
BackgroundSelf-citationLemaire, V., Koehl, M., Le Moal, M., & Abrous, D. N. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.20.11032 · Cited by 1,044
Mammalian Telomeres Resemble Fragile Sites and Require TRF1 for Efficient Replication
Sfeir, A., Kosiyatrakul, S. T., Hockemeyer, D., MacRae, S. L., Karlseder, J., Schildkraut, C. L., & de Lange, T. (2009) · Cell · doi:10.1016/j.cell.2009.06.021 · Cited by 990
Armanios, M., & Blackburn, E. H. (2012) · Nature Reviews Genetics · doi:10.1038/nrg3246 · Cited by 982 · cited 1×
“Similarly, humans suffering from the so-called telomere syndromes, characterized by mutations in telomerase and other telomere maintenance genes, also show premature age-related pathologies (Gilson & Londo~no-Vallejo, 2007; Armanios & Blackburn, 2012).”
BackgroundTelomerase reactivation reverses tissue degeneration in aged telomerase-deficient mice
Jaskelioff, M., Muller, F. L., Paik, J.-H., Thomas, E., Jiang, S., Adams, A. C., Sahin, E., Kost-Alimova, M., Protopopov, A., Cadiñanos, J., et al. (2011) · Nature · doi:10.1038/nature09603 · Cited by 857
White, M. C., Holman, D. M., Boehm, J. E., Peipins, L. A., Grossman, M., & Jane Henley, S. (2014) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2013.10.029 · Cited by 762 · cited 2×
“AAV9-TRF1 treatment does not affect cancer incidence Increasing age is the highest risk factor for cancer development both in humans and in mice (White et al., 2014; Pawelec, 2017).”
BackgroundBernardes de Jesus, B., Vera, E., Schneeberger, K., Tejera, A. M., Ayuso, E., Bosch, F., & Blasco, M. A. (2012) · EMBO Molecular Medicine · doi:10.1002/emmm.201200245 · Cited by 548 · cited 4×
“This pattern of overexpression of TRF1 using AAV9 is consistent with previous reports (Zincarelli et al., 2008; Bernardes de Jesus et al., 2012; Schuster et al., 2014).”
InfluentialSelf-citationTelomerase Reverse Transcriptase Delays Aging in Cancer-Resistant Mice
Tomás-Loba, A., Flores, I., Fernández-Marcos, P. J., Cayuela, M. L., Maraver, A., Tejera, A., Borrás, C., Matheu, A., Klatt, P., Flores, J. M., et al. (2008) · Cell · doi:10.1016/j.cell.2008.09.034 · Cited by 484
Self-citationDisease states associated with telomerase deficiency appear earlier in mice with short telomeres
Herrera, E., Samper, E., Martín‐Caballero, J., Flores, J. M., Lee, H., & Blasco, M. A. (1999) · The EMBO Journal · doi:10.1093/emboj/18.11.2950 · Cited by 471
Self-citationJin, K., Sun, Y., Xie, L., Batteur, S., Mao, X. O., Smelick, C., Logvinova, A., & Greenberg, D. A. (2003) · Aging Cell · doi:10.1046/j.1474-9728.2003.00046.x · Cited by 396 · cited 2×
“Aging and other conditions affect processes of neurogenesis, and this leads to impairment of cognitive function (Drapeau et al., 2003; Jin et al., 2003).”
Backgroundde Jesus, B. B., Schneeberger, K., Vera, E., Tejera, A., Harley, C. B., & Blasco, M. A. (2011) · Aging Cell · doi:10.1111/j.1474-9726.2011.00700.x · Cited by 348 · cited 1×
“Finally, small molecule telomerase activators have been also described to delay some features of aging (Bernardes de Jesus et al., 2011; Harley et al., 2011).”
BackgroundSelf-citationAccumulation of Short Telomeres in Human Fibroblasts Prior to Replicative Senescence
Martens, U. M., Chavez, E. A., Poon, S. S. S., Schmoor, C., & Lansdorp, P. M. (2000) · Experimental Cell Research · doi:10.1006/excr.2000.4823 · Cited by 263 · cited 2×
“When telomeres shorten below a threshold length, they become dysfunctional and this activates a DNA damage response (DDR) at chromosome ends, which in turn leads to the activation of apoptotic and/or cellular senescence programs and thus to the deregulation of many functional processes (Blackburn, 2000; Martens et al.…”
BackgroundTelomere-driven diseases and telomere-targeting therapies
Martínez, P., & Blasco, M. A. (2017) · Journal of Cell Biology · doi:10.1083/jcb.201610111 · Cited by 257 · cited 9×
“Importantly, we have previously demonstrated that stem cell compartments exhibit increased TRF1 expression and that TRF1 is necessary for tissue homeostasis even in the presence of a normal telomere length (Mart ınez et al., 2009; Schneider et al., 2013).”
BackgroundInfluentialSelf-citationMice with Pulmonary Fibrosis Driven by Telomere Dysfunction
Povedano, J. M., Martinez, P., Flores, J. M., Mulero, F., & Blasco, M. A. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.06.028 · Cited by 225 · cited 1×
“In addition, conditional TRF1 abrogation in various mouse tissues has demonstrated the importance of TRF1 for tissue regeneration and tissue homeostasis (Mart ınez et al., 2009; Beier et al., 2012; Schneider et al., 2013; Povedano et al., 2015).”
BackgroundSelf-citationTRF1 binds a bipartite telomeric site with extreme spatial flexibility
Bianchi, A., Stansel, R. M., Fairall, L., Griffith, J. D., Rhodes, D., & de Lange, T. (1999) · The EMBO Journal · doi:10.1093/emboj/18.20.5735 · Cited by 217 · cited 1×
“TRF1 is one of the key components of the shelterin complex (Bianchi et al., 1999).”
BackgroundBär, C., de Jesus, B. B., Serrano, R., Tejera, A., Ayuso, E., Jimenez, V., Formentini, I., Bobadilla, M., Mizrahi, J., de Martino, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms6863 · Cited by 162 · cited 1×
“In particular, we used the AAV9 serotype, also previously used by us to deliver the TERT telomerase gene to many different adult tissues in mice (Bernardes de Jesus et al., 2012; B€ar et al., 2014; Bar et al., 2016).”
MethodSelf-citationProduction, purification and characterization of adeno-associated vectors
Ayuso, E., Mingozzi, F., & Bosch, F. (2010) · Current Gene Therapy · doi:10.2174/156652310793797685 · Cited by 151 · cited 4×
“To this end, we used recombinant AAV vectors, which are nonintegrative (Ayuso et al., 2010), thus leading to a transient TRF1 overexpression.”
BackgroundMethodInfluentialSelf-citationPawelec, G. (2017) · Biogerontology · doi:10.1007/s10522-017-9682-z · Cited by 140
Bär, C., Povedano, J. M., Serrano, R., Benitez-Buelga, C., Popkes, M., Formentini, I., Bobadilla, M., Bosch, F., & Blasco, M. A. (2016) · Blood · doi:10.1182/blood-2015-08-667485 · Cited by 116 · cited 1×
“In particular, we used the AAV9 serotype, also previously used by us to deliver the TERT telomerase gene to many different adult tissues in mice (Bernardes de Jesus et al., 2012; B€ar et al., 2014; Bar et al., 2016).”
MethodSelf-citationBeier, F., Foronda, M., Martinez, P., & Blasco, M. A. (2012) · Blood · doi:10.1182/blood-2012-03-418038 · Cited by 79
Self-citation
Cited by
Telomere shortening rate predicts species life span
Whittemore, K., Vera, E., Martínez-Nevado, E., Sanpera, C., & Blasco, M. A. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1902452116 · Cited by 373
Self-citationZhu, Y., Liu, X., Ding, X., Wang, F., & Geng, X. (2019) · Biogerontology · doi:10.1007/s10522-018-9769-1 · Cited by 255
Metadata
- Authors
- Derevyanko, A., Whittemore, K., Schneider, R. P., Jiménez, V., Bosch, F., & Blasco, M. A.
- Venue
- Aging Cell
- Publisher
- Wiley
- Published
- 2017-09-24
- Volume
- 16
- Issue
- 6
- Pages
- 1353-1368
- ISSN
- 1474-9718 (ISSN-L)
- 1474-9726
- OpenAlex
- W2760601553
- Cited by
- 40
- References
- 27
- FWCI
- 2.40
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.